Weight Loss Injections Compared

How Do Weight Loss Injections Work?

All current injectable weight loss medications belong to the incretin mimetic drug class. They replicate the effects of naturally occurring gut hormones—primarily glucagon-like peptide-1 (GLP-1)—that regulate appetite, glucose metabolism, and energy balance. When injected subcutaneously, these drugs activate receptors in the brain and gut to produce several coordinated effects:

• Central appetite suppression: GLP-1 receptor activation in the hypothalamus and brainstem reduces hunger signals and increases satiety. Patients consistently report feeling less hungry and reaching fullness sooner during meals
• Delayed gastric emptying: The drugs slow the rate at which food leaves the stomach, extending the feeling of fullness after eating and reducing meal frequency
• Improved insulin sensitivity: GLP-1 receptor agonists enhance glucose-dependent insulin secretion and suppress inappropriate glucagon release, improving glycaemic control regardless of diabetes status
• Reduced food reward signalling: Neuroimaging studies show GLP-1 receptor agonists dampen activity in brain reward centres, particularly in response to high-calorie food cues, reducing cravings and hedonic eating
• Increased energy expenditure (triple agonists): Compounds like retatrutide that include glucagon receptor agonism stimulate hepatic thermogenesis and increase basal metabolic rate, adding an energy-output component to the caloric deficit

The net effect is a sustained negative energy balance of approximately 20–35% reduction in daily caloric intake, which produces steady weight loss over 12–18 months of treatment. Beyond helping patients lose weight, these injections also improve blood sugar control, reduce blood pressure, and lower cardiovascular risk markers. For a deeper look at the molecular pathways involved, see our triple-agonist pathway analysis.

Semaglutide — Wegovy & Ozempic

Semaglutide is a GLP-1 receptor agonist and the most widely prescribed weekly injection for obesity treatment worldwide. It is marketed as Wegovy (2.4 mg weekly) for chronic weight management and as Ozempic (0.5–2 mg weekly) for type 2 diabetes. An oral formulation is also available as Rybelsus for type 2 diabetes. While the active molecule is identical across brands, the higher Wegovy dose produces significantly greater weight loss.

Clinical Efficacy

The STEP clinical trial programme established semaglutide’s efficacy across diverse populations. STEP 1 demonstrated 14.9% placebo-adjusted weight loss at 68 weeks in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. STEP 2 showed 9.6% weight loss in patients with type 2 diabetes. STEP 3, which combined semaglutide with intensive behavioural therapy, achieved 16.0% weight loss. STEP 5 confirmed sustained efficacy at 104 weeks with 15.2% weight loss. For a visual breakdown of what these numbers look like in practice, see our Ozempic and Mounjaro before and after results.

Dosing Schedule

Wegovy follows a 16-week dose escalation: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13–16), then maintenance at 2.4 mg weekly. This gradual increase minimises gastrointestinal side effects. Ozempic escalates from 0.25 mg to 0.5 mg at week 4, with optional increases to 1 mg or 2 mg based on glycaemic response. For a focused look at semaglutide dosing protocols and UAE pricing, see our Wegovy price and dosing guide.

Side Effect Profile

Nausea is the most common adverse event (44% in STEP 1), followed by diarrhea (30%), vomiting (24%), and constipation (24%). Most GI side effects are mild to moderate and peak during dose escalation. The discontinuation rate due to adverse events was 7.0% with semaglutide vs 3.2% with placebo. Serious adverse events include cholelithiasis (gallstones) and rare reports of pancreatitis. For a detailed side effect comparison across GLP-1 drugs, see our Ozempic vs Mounjaro vs Wegovy side effects analysis.

Tirzepatide — Mounjaro & Zepbound

Tirzepatide is a dual GLP-1/GIP receptor agonist delivered as a weekly injection that represented a significant step forward in obesity pharmacotherapy. It is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. By simultaneously activating both incretin receptor pathways, tirzepatide produces greater weight loss than selective GLP-1 receptor agonists alone.

Clinical Efficacy

The SURMOUNT trial programme demonstrated tirzepatide’s class-leading efficacy among approved medications. SURMOUNT-1 showed dose-dependent weight loss of 15.0% (5 mg), 19.5% (10 mg), and 22.4% (15 mg) over 72 weeks in adults with BMI ≥30 or ≥27 with comorbidities. Notably, 36.2% of participants on the 15 mg dose achieved ≥25% weight loss. SURMOUNT-2 demonstrated 12.8–14.7% weight loss in patients with type 2 diabetes and obesity. SURMOUNT-3, combining tirzepatide with intensive lifestyle intervention, showed 26.6% weight loss.

Dosing Schedule

Tirzepatide starts at 2.5 mg weekly for 4 weeks, then increases to 5 mg. Subsequent dose escalations to 7.5 mg, 10 mg, 12.5 mg, and 15 mg occur in 4-week intervals based on tolerability and clinical response. The full escalation to 15 mg takes a minimum of 20 weeks. For a detailed comparison with other next-generation drugs, see our Mounjaro injection guide.

Side Effect Profile

Gastrointestinal adverse events are similar to semaglutide: nausea (25–33%), diarrhea (17–23%), vomiting (8–13%), and constipation (11–17%). The GI side effect profile is broadly comparable to semaglutide despite greater efficacy. Treatment discontinuation due to adverse events ranged from 4.3–7.1% across SURMOUNT-1 dose groups. Injection site reactions occurred in 3–7% of patients.

Liraglutide — Saxenda & Victoza

Liraglutide was the first GLP-1 receptor agonist approved for chronic weight management. Marketed as Saxenda (3.0 mg daily) for obesity and Victoza (up to 1.8 mg daily) for type 2 diabetes, it remains widely used despite being superseded in efficacy by newer agents. Its key disadvantage is the requirement for daily injections rather than weekly dosing.

Clinical Efficacy

The SCALE trial programme showed Saxenda produces approximately 8% body weight loss over 56 weeks. SCALE Obesity and Prediabetes (n=3,731) demonstrated 8.0% weight loss vs 2.6% with placebo. SCALE Diabetes showed 5.9% weight loss in patients with type 2 diabetes. While less efficacious than semaglutide or tirzepatide, liraglutide has the longest clinical track record among GLP-1 obesity medications, with approval since 2014 and extensive real-world safety data.

Dosing Schedule

Saxenda requires daily subcutaneous injection, escalating from 0.6 mg daily (week 1) through weekly increases of 0.6 mg to the maintenance dose of 3.0 mg daily at week 5. The shorter half-life of liraglutide (13 hours) necessitates daily dosing, which reduces patient convenience compared to weekly semaglutide or tirzepatide. For a head-to-head comparison, see our Saxenda vs Ozempic analysis.

UAE Availability

Saxenda is the most accessible injectable weight loss medication in the UAE. It is registered with the Ministry of Health and Prevention (MoHAP), widely stocked in hospital and community pharmacies across Dubai, Abu Dhabi, and other emirates, and available through healthcare provider prescription. Monthly cost ranges from approximately AED 800–1,200 depending on pharmacy and whether purchased through insurance. For a broader overview of availability in the region, see our GLP-1 medications UAE guide.

Retatrutide — The Triple-Agonist Research Compound

Retatrutide (LY3437943) is a triple-agonist research peptide that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. It is developed by Eli Lilly and currently in Phase 3 clinical trials. The addition of glucagon receptor agonism differentiates retatrutide from all approved options by adding increased energy expenditure and hepatic thermogenesis to the appetite-suppression mechanism shared by other incretins.

Clinical Efficacy

The Phase 2 trial (Jastreboff et al., NEJM 2023) demonstrated dose-dependent weight loss of 17.5% (4 mg), 22.1% (8 mg), and 24.2% (12 mg) over 48 weeks—the highest weight loss ever recorded for any single agent in a randomised controlled obesity trial. A 2025 Lancet substudy confirmed that the weight loss is predominantly fat mass, with fat mass reductions of up to 21.6% vs placebo.

Research Status

Retatrutide is not FDA-approved and is available only as a research compound or through clinical trial enrolment. The Phase 3 TRIUMPH programme is currently evaluating the 8 mg and 12 mg doses in patients with and without type 2 diabetes. Topline results are expected in 2026. For researchers interested in the compound’s pharmacology, see our retatrutide vs tirzepatide vs CagriSema comparison and side effect profile.

Side Effects Across All Injections

Gastrointestinal adverse events are the hallmark side effects of all GLP-1-based weight loss injections. They arise from the mechanism of action itself—slowed gastric emptying and central appetite suppression produce nausea, and the altered gut motility can cause diarrhea or constipation. These effects are generally dose-dependent and transient.

Serious Adverse Events

Beyond GI symptoms, all GLP-1 receptor agonists carry warnings for pancreatitis (0.1–0.3% incidence), cholelithiasis (gallstones, increased risk with rapid weight loss), and a theoretical risk of medullary thyroid carcinoma based on rodent studies (not confirmed in humans). Tirzepatide and retatrutide additionally show mild increases in heart rate (1–4 bpm on average). The FDA requires all GLP-1 receptor agonists to carry a boxed warning about thyroid C-cell tumours based on the animal data.

Muscle Loss and Body Composition

All injectable weight loss medications produce some degree of lean mass loss alongside fat loss. In the STEP 1 trial, approximately 39% of total weight lost with semaglutide was lean mass. Tirzepatide shows a more favourable ratio, with approximately 18–25% lean mass as a proportion of total weight lost in SURMOUNT trials. Retatrutide’s 2025 body composition substudy showed predominantly fat mass loss, though precise lean-to-fat ratios have not been published. For more on this topic, see our GLP-1 muscle loss and body composition analysis.

Who Should Consider Weight Loss Injections?

Weight loss injections are not a quick fix for cosmetic weight goals. They are prescription weight loss drugs designed for people with clinically significant obesity or weight related health problems who have not achieved adequate results through diet and exercise alone. According to the National Institute for Health and Care Excellence (NICE), pharmacotherapy should be considered when lifestyle changes including healthy eating, physical activity, and behavioural support have proven insufficient.

Clinical Eligibility Criteria

Most clinical studies and prescribing guidelines require a BMI ≥30 (obesity) or BMI ≥27 (overweight) with at least one weight-related comorbidity such as type 2 diabetes, heart disease, obstructive sleep apnea, or hypertension. A primary care physician or specialist should evaluate the patient’s overall health, health conditions, and other medications before prescribing. Not everyone with a high BMI is a suitable candidate—certain health problems may preclude use.

Contraindications and Precautions

Weight loss injections should not be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients with severe kidney problems, a history of pancreatitis, or active gallbladder disease require careful evaluation. Common side effects like feeling sick (nausea) and stomach pain typically resolve during dose escalation, but patients experiencing persistent symptoms should consult their healthcare professional immediately. A heart attack or serious cardiovascular event within the past 6 months is a contraindication for initiating therapy in most guidelines.

At-Risk Populations

Obesity prevalence varies significantly by ethnicity. People of Middle Eastern, South Asian, and African Caribbean origin face higher obesity-related health risks at lower BMI thresholds. The National Institute for Health and Care Excellence recommends lower BMI cut-offs for pharmacotherapy in these populations (BMI ≥27.5 for obesity classification). In the UAE, where a large Middle Eastern and South Asian population lives alongside high obesity rates, healthcare professionals should apply these adjusted thresholds when assessing eligibility for weight loss drugs.

Hair Loss and Other Non-GI Effects

Beyond gastrointestinal symptoms, some patients report hair loss (telogen effluvium) during rapid weight loss with any method, including weight loss injections. This is typically related to the caloric deficit and nutritional changes rather than the drug itself. Hair regrowth usually occurs once weight stabilises. Other medications the patient takes should be reviewed by a primary care provider, as weight loss injections can affect the absorption of oral contraceptives and other drugs.

Diet, Exercise, and Lifestyle Alongside Injections

Weight loss injections achieve the best results when combined with a structured healthy diet and regular exercise programme. Clinical studies consistently show that patients who pair pharmacotherapy with lifestyle changes achieve greater average weight loss and better weight maintenance than those relying on medication alone. A healthy eating plan focused on nutrient-dense whole foods, adequate protein intake, and controlled portions maximises fat loss while preserving lean mass.

Exercise Recommendations

The potential benefits of exercise during injectable therapy extend beyond additional calorie burn. Regular physical activity—at least 150 minutes per week of moderate-intensity exercise such as brisk walking, swimming, or cycling—helps preserve muscle mass during weight loss, improves blood sugar regulation, reduces heart disease risk, and supports mental health. Resistance training 2–3 times per week is particularly important to offset the lean mass loss documented with all weight loss drugs.

Compounded vs Brand-Name Medications

The high demand for weight loss injections has led to supply shortages of brand name Ozempic, Wegovy, and Mounjaro in many markets. Some patients turn to compounded drugs—custom-prepared versions of semaglutide or tirzepatide from compounding pharmacies. While compounded drugs can provide access during shortages, they lack the standardised manufacturing and quality controls of brand-name products. No generic version of semaglutide or tirzepatide is currently available, as both remain under patent protection. Patients should discuss the risks of compounded medications with their healthcare professional.

Cost and UAE Availability

Access to injectable weight loss medications varies significantly across the UAE depending on the specific product, prescriber availability, and insurance coverage. The MoHAP regulates all pharmaceutical products, and weight loss injections require a valid prescription from a licensed healthcare provider.

Insurance coverage for weight loss injections in the UAE remains inconsistent. High demand for these weight loss drugs has created periodic supply shortages, particularly for brand name Ozempic and Mounjaro. Most policies cover Ozempic for diagnosed type 2 diabetes but do not cover its off-label use for weight management. Saxenda coverage for obesity is available through some premium insurance plans but is not standard. Patients should verify coverage with their specific insurer before beginning treatment. For alternatives currently available in Dubai, see our Ozempic alternatives in Dubai guide.

How to Choose the Right Injection

Selecting the optimal weight loss injection depends on multiple factors that should be discussed with a qualified healthcare professional. These weight loss drugs are not interchangeable—each has distinct clinical studies supporting its use in different patient populations:

• Weight loss targets: Patients requiring ≥20% body weight loss may benefit most from tirzepatide (Zepbound) given its superior efficacy data. Those needing more moderate weight loss (10–15%) may find semaglutide (Wegovy) sufficient
• Comorbidities: Patients with type 2 diabetes, obstructive sleep apnoea, heart disease, or high blood sugar may benefit from the dual glucose-lowering and weight loss effects of tirzepatide (Mounjaro) or semaglutide (Ozempic). Semaglutide has additional FDA approval for cardiovascular risk reduction in the SELECT trial and obstructive sleep apnea (Zepbound)
• Injection convenience: Weekly injections (semaglutide, tirzepatide) offer significantly better convenience than daily liraglutide (Saxenda). Adherence data consistently shows higher persistence with weekly formulations
• Access and cost: In the UAE, Saxenda is the most accessible and affordable option. Ozempic is widely available but technically indicated for diabetes. Mounjaro in Dubai is expanding but supply-limited
• Tolerability: Patients who experience significant GI side effects on one agent may tolerate another differently. Tirzepatide may offer a slightly more favourable nausea profile relative to its weight loss magnitude compared with semaglutide

What Happens When You Stop Injections?

Weight gain after discontinuation is a significant clinical challenge with all injectable weight loss medications. Patients who lose weight on these drugs face substantial rebound risk. The STEP 1 extension study showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. Similar rebound patterns have been observed with tirzepatide in SURMOUNT-4, where patients who switched from tirzepatide to placebo regained approximately 14% body weight over 36 weeks.

This rebound occurs because the medications treat the biological drivers of obesity (dysregulated appetite signalling, metabolic set points) without permanently correcting them. When the drug is removed, the underlying physiology reasserts itself. Current clinical guidance increasingly frames GLP-1 medications as long-term or indefinite treatments for chronic obesity, analogous to antihypertensives for blood pressure. For a detailed analysis of the discontinuation data, see our GLP-1 weight regain research review.

Next-Generation Compounds in Development

The injectable obesity drug pipeline includes several compounds that may rival or exceed the efficacy of current options:

• Retatrutide (Eli Lilly): Triple-agonist (GLP-1/GIP/GCGR) in Phase 3 TRIUMPH trials. 24.2% weight loss in Phase 2—the highest ever recorded for a single agent
• CagriSema (Novo Nordisk): Fixed-dose combination of semaglutide 2.4 mg + cagrilintide (amylin analogue). Phase 3 REDEFINE programme showed up to 22.7% weight loss. Expected approval 2026–2027. See our CagriSema vs tirzepatide comparison
• Survodutide (Boehringer Ingelheim): Dual GLP-1/glucagon agonist. Phase 2 showed 18.7% weight loss. Particularly promising for MASH (metabolic-associated steatohepatitis). See our survodutide analysis
• Amycretin/Zenagamtide (Novo Nordisk/Zealand): Unimolecular GLP-1/amylin dual agonist. Early Phase 1/2 data showed 13% weight loss in 12 weeks. See our zenagamtide analysis

For a comprehensive tracker of all obesity drugs in development, see our obesity drug pipeline timeline.